Our goal at Cardior is to identyfy and counteract the molecular mechanisms of the broad area of iscemic-induced heart faliure as well as specific cardiac diseases such as hypertropic and dilated cardiomyopathies.
Our innovation is based on a novel class of RNA therapeutics targeting so called non-coding RNAs that are able to act on several key disease pathways simultaneously, triggering a concerted therapeutic effect against key hallmarks of heart disease including:
- Cardiac hypertrophy
- Impaired contractility
- Reduced vascularization
Although non-coding RNAs (ncRNAs) are not translated into proteins, they are critical for the regulation of important cellular processes and their dysregulation is a hallmark of many diseases. With its deep knowledge in RNA biology, Cardior has developed a therapeutic approach to restore normal levels and functions of these critical players in the pathological processes of cardiac diseases.
For more information, please contact:
Phone: +45 2270 5065